November 6th 2024
AMN, a rare disease, is characterized by dark reddish, wedge-shaped macular lesions.
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types
View More
(COPE) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
Current, Relevant, Useful: Key Takeaways from the CRU Eye Symposium (CME Credit)
View More
Current, Relevant, Useful: Key Takeaways from the CRU Eye Symposium (COPE Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
EnVision Summit
February 14-17, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
FDA issues CRL for aflibercept 8 mg from Regeneron Pharmaceuticals
The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler."
AOA 2023: Stay current with the updated AMD landscape
Mohammad Rafieetary, OD, FAAO, shares brief highlights from his 2023 AOA presentation, "AMD updates: Staying current with its landscape," which he co-presented with Jay Haynie, OD, FAAO.
AOA 2023: Eyechiatry: The psychology of vision loss
Mohammad Rafieetary, OD, FAAO, shares brief highlights from his 2023 AOA presentation, "Do you practice Eyechiatry? The psychology of vision loss," which he co-presented with Roya Attar, OD, MBA.
AOA 2023: Take a look into white dot syndrome
Roya Attar, OD, discussed, "White dot syndrome: More common than you think," which she will be presenting at AOA 2023 in Washington, DC.
AOA 2023: The skinny on intravitreal injections for retinal diseases
June 22nd 2023Over the past decade the progress in retinal disease treatments has exploded with increased numbers of approved pharmaceutical compounds, resulting in more options for treating retinal disease with intravitreal agents and more are in the pipeline.
Into the periphery with lattice retinal degeneration
June 6th 2023Lattice retinal degeneration is the most significant peripheral retinal change associated with retinal detachment. Generally, it is a stable condition without symptoms unless the complication of a retinal tear develops, which can lead to retinal detachment. There are a number of presentations among patients, who can be of a young age and have almost any refractive correction.
Alimera nabs US commercial rights for Yutiq
May 18th 2023Today, Alimera Sciences announced that they have acquired the US commercial rights of Yutiq (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis. Yutiq now joins Iluvien (fluocinolone acetonide intravitreal insert) 0.19 mg for DME in Alimera’s retina portfolio.
DR:EAM study: Exploring eye drops for diabetic retinopathy
The DR:EAM study in investigating novel eye drop OTT-166 for the treatment of diabetic retinopathy in hopes of reducing treatment burden for patients.
ASCRS 2023: Manifestations of chronic renal insufficiency in the eye
May 6th 2023Umida F. Mavlyanova, PhD, in a presentation at the American Society for Cataract and Refractive Surgery’s annual meeting in San Diego, detailed how patients diagnosed with end-stage chronic renal failure displayed deceased blood flow in the orbital artery, the central artery of the retina and the posterior short ciliary arteries.
ARVO 2023: Human donor tissue to identify mechanism of retinal pigment epithelium death
Deborah Ferrington, PhD, shares a brief overview of her presentation on identifying the mechanism responsible for the death of the retinal pigment epithelium.